Informations:
Erreur:
ID
36389
Description
Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703); ODM derived from: https://clinicaltrials.gov/show/NCT02332499
Lien
https://clinicaltrials.gov/show/NCT02332499
Mots-clés
Versions (1)
- 09/05/2019 09/05/2019 -
Détendeur de droits
See clinicaltrials.gov
Téléchargé le
9 mai 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Metastatic Colorectal Cancer NCT02332499
Eligibility Metastatic Colorectal Cancer NCT02332499
- StudyEvent: Eligibility
Similar models
Eligibility Metastatic Colorectal Cancer NCT02332499
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Informed Consent
Item
1. signed and dated informed consent；
boolean
C0021430 (UMLS CUI [1])
Adenocarcinoma of colon | Adenocarcinoma of rectum
Item
2. histological or cytological documentation of adenocarcinoma of the colon or rectum；
boolean
C0338106 (UMLS CUI [1])
C0149978 (UMLS CUI [2])
C0149978 (UMLS CUI [2])
Colorectal cancer metastatic TNM clinical staging | Measurable Disease
Item
3. subjects with metastatic colorectal cancer (stage iv),with measurable disease (using recist1.1)；
boolean
C0948380 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C1513041 (UMLS CUI [2])
C3258246 (UMLS CUI [1,2])
C1513041 (UMLS CUI [2])
Disease Progression Following Standard therapy | Fluorouracil | Fluorouracil Derivative | oxaliplatin | irinotecan
Item
4. progression during or within 3 months following the last administration of approved standard therapies which must include fluorouracil or its derivatives, oxaliplatin, irinotecan；
boolean
C0242656 (UMLS CUI [1,1])
C0332282 (UMLS CUI [1,2])
C2936643 (UMLS CUI [1,3])
C0016360 (UMLS CUI [2])
C0016360 (UMLS CUI [3,1])
C1527240 (UMLS CUI [3,2])
C0069717 (UMLS CUI [4])
C0123931 (UMLS CUI [5])
C0332282 (UMLS CUI [1,2])
C2936643 (UMLS CUI [1,3])
C0016360 (UMLS CUI [2])
C0016360 (UMLS CUI [3,1])
C1527240 (UMLS CUI [3,2])
C0069717 (UMLS CUI [4])
C0123931 (UMLS CUI [5])
ECOG performance status | Life Expectancy
Item
5. ecog ps:0-1,life expectancy of more than 3 months；
boolean
C1520224 (UMLS CUI [1])
C0023671 (UMLS CUI [2])
C0023671 (UMLS CUI [2])
Organ function
Item
6. main organs function is normal；
boolean
C0678852 (UMLS CUI [1])
Organ function
Item
7. main organs function is normal；
boolean
C0678852 (UMLS CUI [1])
anlotinib
Item
1. prior treatment with anlotinib；
boolean
C4519250 (UMLS CUI [1])
Major surgery | Incisional biopsy | Traumatic injury
Item
2. major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study drug；
boolean
C0679637 (UMLS CUI [1])
C0184922 (UMLS CUI [2])
C3263723 (UMLS CUI [3])
C0184922 (UMLS CUI [2])
C3263723 (UMLS CUI [3])
Metastatic malignant neoplasm to brain
Item
3. known brain metastases；
boolean
C0220650 (UMLS CUI [1])
Disease Severe Uncontrolled
Item
4. patients with severe and failed to controlled diseases；
boolean
C0012634 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
C0205082 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
Thromboembolism of vein
Item
5. patients occurred venous thromboembolic events within 6 months；
boolean
C1997614 (UMLS CUI [1])